Fluvoxamine is a selective serotonin reuptake inhibitor that exerts antidepressant activity by inhibiting the reuptake of serotonin, or 5-hydroxytryptamine, in the central nervous system. Fluvoxamine shows negligible affinity for other neurotransmitter reuptake systems, [1] [2] [3] [4] so it may have advantages over other antidepressants in the treatment of depression. For example, tricyclic antidepressant (TCA) is associated with an increased risk of cardiovascular events. [5] [6] [7] [8] [9] However, accumulating evidence suggests that fluvoxamine may increase cardiovascular risk through inhibition of the human ether-a-go-go related (HERG) potassium channel.
However, accumulating evidence suggests that fluvoxamine may increase cardiovascular risk through inhibition of the human ether-a-go-go related (HERG) potassium channel. 10) The drug may also be associated with ventricular arrhythmia.
11) Pharmacological blockade of cardiac muscle voltage-gated K ϩ channels (Kv channels) is associated with adverse cardiac arrhythmias, suggesting that fluvoxamine may interact with cardiac Kv channels. However, the exact effects of fluvoxamine on cardiac Kv channels remain to be elucidated.
Kv1.5 is a cardiovascular-specific Kv channel isoform. It has an important role in determining the length of cardiac action potentials, and is a target of antiarrhythmic drugs. 12) Kv1.5 is rapidly activated and is difficult to inactivate, so it contributes to the repolarization of atrial action potentials. Kv1.5 dysfunction results in prolonged cardiac action potentials, eventually leading to cardiac arrhythmias with serious morbidity. [13] [14] [15] In this study, we investigated whether fluvoxamine interacts with Kv1.5 cloned from rat brain and determined the mechanisms by which fluvoxamine acts on Kv1.5.
MATERIALS AND METHODS

Stable Transfection and Cell Culture
Chinese hamster ovary (CHO) cells expressing Kv1.5 channels from rat brain were used for electrophysiological recordings. 16) Kv1.5 cDNA 17) was cloned into the plasmid expression vector pCR3.1 (Invitrogen Corp., San Diego, CA, U.S.A.). CHO cells were transfected with Kv1.5 cDNA using FuGENE6 reagent (Boehringer Mannheim, Indianapolis, IN, U.S.A.).
Transfected cells were cultured in Iscove's modified Dulbecco's medium (Invitrogen Corp.) supplemented with 10% fetal bovine serum, 2 mM glutamine, 0.1 mM hypoxanthine, 0.01 mM thymidine, and 300 mg/ml G418 (A.G. Scientific, San Diego, CA, U.S.A.) in 95% humidified air-5% CO 2 at 37°C. Cultures were passaged every 4-5 d by brief trypsinethylenediaminetetraacetic acid treatment, seeded onto glass coverslips (diameter: 12 mm, Fisher Scientific, Pittsburgh, PA, U.S.A.) in a Petri dish, and used for electrophysiological recordings after 12-24 h.
Electrophysiological Recordings Kv1.5 currents were recorded from CHO cells using a whole-cell patch-clamp technique 18) at room temperature (22-23°C). Micropipettes fabricated from glass capillary tubing (PG10165-4; World Precision Instruments, Sarasota, FL, U.S.A.) with a doublestage vertical puller (PC-10; Narishige, Tokyo) had a tip resistance of 2-3 MW when filled with pipette solution. Wholecell currents were amplified with a MultiClamp 700B amplifier (Molecular Devices, Sunnyvale, CA, U.S.A.), digitized with Digidata 1440A (Molecular Devices) at 5 kHz, and lowpass filtered with a four-pole Bessel filter at 2 kHz. Capacitive currents were cancelled and series resistance was compensated at 80% with the amplifier. Leak subtraction was not used, and voltage commands were generated and acquisition of data was controlled with pClamp 10.1 software (Molecular Devices) running on an IBM-compatible Pentium computer. The recording chamber (RC-13, Warner Instrument Corp., Hamden, CT, U.S.A.) was continuously perfused with bath solution (see below for composition) at a rate of 1 ml/min.
Solutions and Drugs
The intracellular pipette solution for whole-cell recordings contained 140 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM N-(2-hydroxyethyl)piperazine-NЈ-2-ethanesulfonic acid (HEPES), and 10 mM ethylene glycol bis(2-aminoethyl ether)-N,N,NЈNЈ-tetraacetic acid, and was adjusted to pH 7.3 with KOH. The bath solution for whole-cell recordings contained 140 mM NaCl, 5 mM KCl, 1.3 mM CaCl 2 , 1 mM MgCl 2 , 20 mM HEPES and 10 mM glu-cose and was adjusted to pH 7.3 with NaOH. Fluvoxamine (Sigma Chemical Co., Saint Louis, MO, U.S.A.) was dissolved in ethanol at 30 mM and further diluted into the bath solution. The final concentration of ethanol in the bath solution was less than 0.1%, which had no effect on the Kv1.5 currents.
Data Analysis Data were analyzed with Origin 7.0 (OriginLab Corp., Northampton, MA, U.S.A.) and Clampfit 10.2 software (Molecular Devices). Steady-state activation curves were fitted with the Boltzmann equation:
where k represents the slope factor, V is the test potential, and V 1/2 is the potential at which the conductance was halfmaximal. The activation time constant was calculated by fitting the last 50% of activation (i.e., the peak amplitude rise from 50 to 100%) with a single exponential function. The IC 50 and Hill coefficients (n) were obtained by fitting concentration dependence data to the following equation:
where I(%) is the percent inhibition of the current (I(%)ϭ[1ϪI drug /I control ]ϫ100) at the test potential, and [D] is drug concentration. The binding (k ϩ1 ) and unbinding (k Ϫ1 ) rate constants were obtained from the following equations: (4) in which t D is the drug-induced time constant. The druginduced time constant and deactivation time constant were determined by fitting to the sum of the exponentials:
in which t 1 , t 2 , and t n are the time constants; A 1 , A 2 , and A n are the amplitudes of each component of the exponential; and B is the baseline value.
To investigate the voltage dependence of Kv1.5 inhibition, the relative current was plotted as a function of membrane potential and the percent inhibition data between 0 and ϩ50 mV were fitted using the Woodhull equation 19) :
where K D (0) represents the apparent affinity at 0 mV, z is the charge valence of the drug, d is the fractional electrical distance, F is Faraday's constant, R is the gas constant, and T is the absolute temperature. A value of 25.4 mV was used for RT/F at 22°C. Equation 6 can be modified to a linear transformation as follows:
Results were expressed as meanϮstandard error of the mean (S.E.M.). Paired or unpaired Student's t-test and analysis of variance (ANOVA) were used for statistical analysis. A value of pϽ0.05 was considered statistically significant.
RESULTS
Concentration
-Dependent Inhibition of Kv1.5 by Fluvoxamine As shown in Fig. 1A , Kv1.5 currents were activated under control conditions with a rapid rise to a peak, followed by slow inactivation, as reported previously.
16) The dominant time constant of activation under control conditions was 2.11Ϯ0.19 ms (nϭ4) with a 250-ms depolarizing pulse from a holding potential of Ϫ80 to ϩ50 mV. In the presence of 3 mM fluvoxamine, the time constant of activation was 1.96Ϯ0.21 ms (nϭ4), which indicated that the activation kinetics was not significantly modified by fluvoxamine. Assays at different concentrations of fluvoxamine (0.3, 1, 3, 10, 30 mM), showed that Kv1.5 current inhibition was concentration-dependent (Fig. 1B) , when inhibition of current was measured at the end of a 250-ms pulse of ϩ50 mV. The IC 50 was 2.0Ϯ0.13 mM, and the Hill coefficient was 0.7Ϯ0.03, as determined by a nonlinear, least-squares fit of the Hill equation to the individual data points (nϭ4). In solutions containing different concentrations of fluvoxamine, inhibition of Kv1.5 reached a steady state within 2 min. Washout by perfusion of drug-free solution was also reached within 2 min, with currents recovering to 83.5Ϯ5.7% of the control value (nϭ4), indicating that effects of fluvoxamine were largely reversible.
State-Dependent Inhibition of Kv1.5 by Fluvoxamine As shown in Fig. 2 , state dependence of inhibition of Kv1.5 by fluvoxamine was examined. To test interaction between fluvoxamine and a closed or resting-state Kv1.5 channel, cells were maintained at Ϫ80 mV holding potential for 2 min without stimulation pulse in the presence of 3 mM fluvoxamine. Control current was measured by stimulation pulse before application of 3 mM fluvoxamine. First, second and fifth currents are the selected currents measured by the successive reapplication of stimulation pulses after a 2-min rest in the presence of 3 mM fluvoxamine. As shown in Fig. 2A , the current inhibition of Kv1.5 by fluvoxamine was detected at the first pulse (1st trace) after a 2-min rest in the presence of 3 mM fluvoxamine but the maximum inhibition of Kv1.5 current was measured at the second pulse (2nd trace): 38.6Ϯ3.6% inhibition at the first pulse and 55.3Ϯ3.1% inhibition at the second pulse, respectively, measured at the end of a 250-ms pulse of ϩ50 mV. The value of inhibition of Kv1.5 current at the second pulse (55.3Ϯ3.1% inhibition) is not significantly different from the value which was measured by applying 250-ms depolarizing pulses from a holding potential of Ϫ80 to ϩ50 mV every 10 s without 2-min rest in the presence of 3 mM fluvoxamine ( Fig. 1) : 58.6Ϯ3.9% inhibition (nϭ4, pϽ0.05). This result strongly suggests that some inhibition of the Kv1.5 channel occurred during the interpulse interval when the majority of Kv1.5 channels were either in a closed/resting state or nonconducting state.
Voltage-Dependent Inhibition of Kv1.5 by Fluvoxamine Figure 3 shows the effect of 3 mM fluvoxamine on the current-voltage (I-V) relationship. Under control conditions, the Kv1.5 current was activated at pulses greater than Ϫ30 mV, and the steady-state I-V relationship was sigmoidal at potentials between Ϫ30 and 0 mV (Figs. 3A, C) . Inhibition of Kv1.5 currents by 3 mM fluvoxamine was observed over the entire voltage range of Kv1.5 activation (Figs. 3B, C) . A high degree of inhibition and a strong voltage dependence were observed between Ϫ30 and 0 mV, the voltage range for channel opening, by plotting percent inhibition (see Materials and Methods) versus potential (Fig. 3D) . Although Kv1.5 was fully activated between 0 and ϩ50 mV, inhibition continued to increase with a slight voltage dependence: 49.3Ϯ2.5% inhibition at 0 mV, and 57.5Ϯ3.7% at ϩ50 mV (nϭ4, pϽ 0.05). Assuming that fluvoxamine interacts intracellularly with Kv1.5, we generated a linear curve by fitting the data at potentials greater than 0 mV using a linear transformation of the Woodhull equation (see Materials and Methods). The solid lines in Fig. 3D show a fitted curve that yielded an electrical distance (d) of 0.16Ϯ0.02 (nϭ4).
Time-Dependent Inhibition of Kv1.5 by Fluvoxamine Figure 4A shows the effect of fluvoxamine on a time course of the channel current during a 250-ms depolarizing pulse at
and an unbinding rate constant (k Ϫ1 ) of 18.4Ϯ3.8 s Ϫ1 (nϭ4). The theoretical K D value derived by k Ϫ1 /k ϩ1 yielded 13.1 mM, which is not close to the experimental IC 50 value of 2.0 mM for fluvoxamine obtained from the concentration-dependent curve shown in Fig. 1 .
To further investigate the time-dependent inhibition of Kv1.5 by fluvoxamine, Kv1.5 current deactivation kinetics was studied. Figure 5A shows a representative superimposed tail current under control conditions and with 3 mM fluvoxamine, recorded with a 250-ms repolarizing pulse at Ϫ40 mV, after a 250-ms depolarizing pulse of ϩ50 mV from a holding potential of Ϫ80 mV. These currents were well fitted to single exponential functions. Under control conditions, the tail current declined quickly with a time constant of 14.6Ϯ 1.5 ms (nϭ4) and was nearly completely deactivated during a 250-ms repolarizing pulse of Ϫ40 mV. In the presence of 3 mM fluvoxamine, the initial peak amplitude of the tail current was reduced, and the subsequent decline in the current was slower (28.8Ϯ2.7 ms, nϭ4), resulting in the tail crossover phenomenon. Figure 5B summarizes the time constants obtained at repolarizing pulses of Ϫ40 mV. Fluvoxamine significantly increased the deactivation time constants of Kv1.5 at repolarizing pulses of Ϫ40 mV (nϭ4, pϽ0.05). Figure 6A shows the original current traces in the absence or presence of a 2-min exposure to 3 mM fluvoxamine, obtained after applying 20 repetitive 125-ms depolarizing pulses of ϩ50 mV from a holding potential of Ϫ80 mV at 1 and 2 Hz. Figure 6B shows the normalized current amplitudes at 1 and 2 Hz in the absence and presence of 3 mM fluvoxamine during application of the pulse trains. Under control conditions, the peak amplitude of the Kv1.5 current decreased slightly by 14.4Ϯ2.2% (nϭ4) at 1 Hz and by 22.9Ϯ4.3% (nϭ4) at 2 Hz. In the presence of 3 mM fluvoxamine, the peak amplitude of Kv1.5 decreased progressively in an use-dependent manner by 54.2Ϯ3.7% (nϭ4) at 1 Hz and by 64.3Ϯ3.5% (nϭ4) at 2 Hz. These results suggest that fluvoxamine inhibits current through Kv1.5 in an use-dependent manner. For an analysis of a frequency-dependent inhibition of Kv1.5 by fluvoxamine without contamination of the decline of the current under control conditions, the relative currents (I Fluvoxamine /I Control ) at (A) Superimposed current traces were produced by applying 250-ms depolarizing pulses from a holding potential of Ϫ80 to ϩ50 mV, followed by a 250-ms repolarizing pulse to Ϫ40 mV every 10 s in the absence or presence of 3 mM fluvoxamine. Control current is the final current before termination of stimulation and addition of 3 mM fluvoxamine to the bath. 1st, 2nd and 5th currents are the currents measured by the successive application of pulses after a 2-min rest in the presence of 3 mM fluvoxamine. (B) Summary data obtained from (A). Percent inhibitions of 1st and 2nd currents measured at the end of the 250-ms depolarizing pulses were used as an index of steady-state inhibition (nϭ4; * pϽ0.05 versus 1st data). Data are expressed as meanϮS.E.M.
Use-Dependent Inhibition of Kv1.5 by Fluvoxamine
1 and 2 Hz were plotted (Fig. 6C) . The weak frequencydependent inhibition of Kv1.5 current was detected at two frequencies, 1 and 2 Hz. blockade, with no effect on Kv1.5 activation kinetics, suggesting that fluvoxamine does not bind to the closed or resting state of Kv1.5 and that the drug preferentially interacts with the open state. Kv1.5 inhibition by fluvoxamine was highly voltage-dependent and increased steeply in the voltage range of channel activation. The voltage-dependent inhibition of Kv1.5 by fluvoxamine supports the model that Kv1.5 inhibition by fluvoxamine preferentially occurs after channels are open. 16, 20) In addition, fluvoxamine slowed the deactivation time course, resulting in a tail crossover phenomenon. This can be explained if the dissociation rate of fluvoxamine is lower than the transition rate between the open and the closed (or resting) states under control conditions. Thus, the tail crossover phenomenon also suggests an interaction between fluvoxamine and the open state of Kv1.5, as previously reported. 16, [20] [21] [22] [23] Inhibition was use-dependent, with effects enhanced at higher rates of channel activation. Usedependent inhibition is a feature of open channel blockers, because when channels open more frequently, blockers have a higher chance of binding to channel pores. 16, 20, 24) Taken together, the results are consistent with fluvoxamine acting on the open state of Kv1.5 and suggest that fluvoxamine acts as an open channel blocker of Kv1.5. However, the several data were not consistent with the pure open-channel blocking scheme based on the following lines of evidence. 1) As shown in Fig. 2 , the extents of inhibition of Kv1.5 by fluvoxamine with or without 2-min rest are different and finally, the drug-induced inhibition of Kv1.5 current additionally increases during the transition between the open and closed/ resting state of Kv1.5 channel. These results strongly suggest that fluvoxamine may also interact with Kv1.5 channel in a closed/resting or nonconducting state after deactivation, as long as the Kv1.5 channels have already opened at least once in the presence of the fluvoxamine. 2) On the basis of a pure open-channel blocking scheme, the apparent rate constants for binding (k ϩ1 ) and unbinding (k Ϫ1 ) and the theoretical K D value were calculated from the Eqs. 3 and 4 (Fig. 4) . However, the theoretical K D value is far from the experimental IC 50 value obtained from the concentration-dependent curve shown in Fig. 1 . This suggests that the inhibition of Kv1.5 channel by fluvoxamine may not be explained by the simple open-channel blocking mechanism. 3) Although the use-dependent inhibition as a feature of open channel blocker was detected (Fig. 6) , the frequency dependence of Kv1.5 inhibition by fluvoxamine is very weak at two frequencies, 1 and 2 Hz. These results also may be explained not by the pure open-channel blocking mechanism but by interactions between fluvoxamine and the multiple-state Kv1.5 channel. Taking all these results together, the inhibition of Kv1.5 currents by fluvoxamine may occur via interactions with at least two states, open and closed/inactivated states of Kv1.5 channel. These kind of mixed channel-state dependence of channel inhibition by fluvoxamine was reported previously.
10) The characteristic of HERG block by fluvoxamine is a closed channel blockade with IC 50 of 3.8 mM and the blockade is also dependent on open and inactivated channel states showing mixed channel-state dependence of inhibition. Although further studies are necessary for the elucidation of the fluvoxamine binding site on HERG channels, the binding of fluvoxamine at the outer mouth of HERG channel has been suggested to interfere with the transition from open to inactivate, which involves closure of an extracellular inactivation gate. 10, 25, 26) These reports also support the present study showing interactions between fluvoxamine and at least two states, open and closed/inactivated states of Kv1.5 channel.
An additional small degree of inhibition was detected in the positive to 0 mV voltage range, despite the complete activation of Kv1.5. This weak but significant voltage-dependent inhibition was considered to be a consequence of transmembrane electrical field effects on the interaction between fluvoxamine and Kv1.5. If a positively charged drug moves into the transmembrane electric field from within, inhibition should increase upon depolarization because of electrostatic repulsion between the positively charged compound and the membrane depolarizing potential. This will occur in the voltage range in which channels are opening and fully activated. At an intracellular pH of 7.3, fluvoxamine is mainly positively charged because it is a weak base with pK a ϭ9.39.
27)
When positively charged fluvoxamine interacts intracellularly with Kv1.5, it appears to move into the transmembrane electric field from within. Thus, inhibition is expected to increase at higher depolarizing potentials because of electrostatic repulsion in the voltage range in which the channels are fully activated. The d value of 0.16 for the small voltage dependence indicated that positively charged fluvoxamine senses 16% of the applied transmembrane electrical field from the intracellular side. This value is similar to the d values of 0.16-0.19 obtained in previous experiments with open channel blockers of Kv1.5. 16, 21, 28, 29) Although fluvoxamine is thought to be safer than other antidepressants such as TCA, [5] [6] [7] [8] [9] it has been reported to inhibit the HERG potassium channel 10) and may be related to ventricular arrhythmia.
11) Based on pharmacokinetics, the therapeutic plasma concentration of fluvoxamine is reported to be less than 0.8 mM in depressed human patients. [30] [31] [32] We found an IC 50 value (2.0 mM) for fluvoxamine blocking Kv1.5 that was higher than that of the therapeutic plasma concentrations. However, significant inhibitions of Kv1.5 currents at concentrations of 0.3 or 1 mM were detected. Furthermore, we examined the effects of fluvoxamine on Kv1.5 in a CHO cell line, whose phospholipid composition may be different from that of human native cardiac myocytes, affecting fluvoxamine-induced Kv1.5 blockade. Furthermore, drug concentrations in tissues may be higher than in plasma because of high lipophilicity and affinity for adipose tissues. Therefore, the extent of fluvoxamine blocking of Kv1.5 under physiological conditions may be underestimated. Therefore, the fluvoxamine-induced block of the Kv1.5 channel could be clinically relevant in the upper range of the therapeutic plasma concentrations that are observed in the treatment of depressed patients. Finally, in cardiomyocytes, fluvoxamine most likely leads to cardiac disorder through blocking the Kv1.5 channel that results in a significant prolongation of the action potential or that affects cardiac excitability.
In conclusion, we describe for the first time the effects of fluvoxamine on the Kv1.5 channel expressed in CHO cells. Detailed study of the interaction kinetics between fluvoxamine and Kv1.5 suggest that fluvoxamine is an open-and closed/inactivated-channel blocker for Kv1.5 in a concentration-, voltage-, time-, and use-dependent manner. Thus, because of arrhythmogenic risk, caution is advised when using fluvoxamine to treat depressed patients.
